Clinical trials: Empagliflozin
Type II Diabetes in Subjects BMI 27 to 32
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
Investigators aim to show that Roux-en-Y Gastric Bypass (RYGB) is superior to best medical treatment in reaching well-defined treatment end points in Asian subjects of BMI 27-32 with type 2 Diabetes (DM2).
- Trial name
- NCT02041234
- Testing
- Roux-en-Y Gastric Bypass (RYGB), Incretin analogues, Xenical
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Khoo Teck Puat Hospital
Bioequivalence Study in Healthy Subjects
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 1000 mg Tablets Under Fed Conditions.
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- ACL24-PC020 (NCT07633041)
- Testing
- Synjardy 12.5/1000 mg tablet, Empagliflozin/metformin 12.5/1000 mg
- Where
- Mexico
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ADIUM
Healthy
Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin
The objective of the study is to investigate the drug-drug interaction potential between BI 10773 and simvastatin.
- Trial name
- NCT01304329
- Testing
- BI 10773, simvastatin
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin…
- Trial name
- NCT07076056
- Testing
- DW1026C1, DW1026C2, DW1026S
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Glycogen Storage Disease Type I, Glucose 6 Phosphatase Deficiency
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
Treatment of neutropenia of G6PC3 and Glycogenosis type 1b patients with empagliflozin
- Trial name
- GLYCO-1B (NCT04138251)
- Testing
- Empagliflozin
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Healthy
Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers
Study to investigate the relative bioavailability of BI 10773 and of linagliptin after concomitant multiple oral administration of 50 mg BI 10773 tablets and 5 mg linagliptin in comparison to 50 mg BI 10773 and 5 mg linagliptin…
- Trial name
- NCT02172222
- Testing
- BI 10773, Linagliptin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Kidney Injury
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
To investigate the potential of preoperative initiation (3 days) and perioperative continuation (until day 2 after surgery) of empagliflozin(sodium glucose co transporter 2 inhibitor(SGLT-2i)) 10 mg daily to reduce the acute…
- Trial name
- MERCURI (NCT06825156)
- Testing
- Empagliflozin 10 MG
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Heart Failure
ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure…
- Trial name
- NCT07379788
- Testing
- Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO], Empagliflozin10Mg Tab
- Where
- Saudi Arabia
- Volunteers
- 180 people
- Sponsor
- Rehab Werida
Hematocrit Change, Cardiovascular Prevention
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
The aim of this study is to investigate the hypothesis that treatment with empagliflozin may have an impact on red blood cell 2,3-biphosphoglycerate levels affecting tissue oxygen supply and thus mediating part of the cardio- and…
- Conditions
- Hematocrit Change, Cardiovascular Prevention, Empagliflozin, SGLT2-Inhibitors
- Trial name
- NCT06284850
- Testing
- Empagliflozin10Mg Tab
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Aristotle University Of Thessaloniki
Nephrotic Syndrome
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome.
- Trial name
- SGLT2-NS (NCT07214818)
- Testing
- Dapagliflozin, Empagliflozin, Standard Therapy
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Mansoura University
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
the pharmacokinetics, pharmacodynamics and safety and tolerability of single and multiple oral doses of BI 10773 at low dose once daily (q.d.) and high dose q.d.
- Trial name
- NCT01316341
- Testing
- BI10773
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.
- Trial name
- NCT05262764
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 1,200 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to…
- Trial name
- NCT01210001
- Testing
- BI 10773
- Where
- 68 sites in United States, Canada and 5 more
- Volunteers
- 499 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when…
- Trial name
- NCT06083675
- Testing
- Semaglutide, Empagliflozin, Metformin
- Where
- 100 sites in United States, Brazil and 11 more
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin…
- Trial name
- NCT05102071
- Testing
- empagliflozin, metformin, sulfonylurea
- Where
- United States
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy Type 2
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. Diabetic kidney disease (DKD) is a clinical diagnosis based upon the presence of reduced glomerular filtration rate (GFR)…
- Trial name
- SGLT2i VS ACEi (NCT05373004)
- Testing
- Empagliflozin 25 MG, Enalapril Maleate 20 mg
- Volunteers
- 212 people
- Sponsor
- Omar Tarek Elfarargi
Atrial Fibrillation (AF), Hypertension
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
Heart failure is the most important clinical endpoint event in atrial fibrillation (AF). Patients with AF complicated by heart failure have a significantly higher risk of all-cause mortality and cardiovascular mortality compared…
- Trial name
- NCT07482020
- Testing
- SGLT-2 inhibitors
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Huashan Hospital
Thrombosis
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically altered the management of heart failure (HF) patients, independently of their ejection fraction and glycemic status.
- Trial name
- SOTATHROMBUS (NCT06618976)
- Testing
- Sotagliflozin, Empagliflozin
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease, Diabete Mellitus
The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.
The study is to compare the effects of SGLT-2 inhibitors and other oral hypoglycemic agents in patients with coronary heart disease and diabetes mellitus undergoing percutaneous coronary intervention.
- Trial name
- NCT05333159
- Testing
- SGLT2 inhibitor
- Where
- China
- Volunteers
- 1,424 people
- Sponsor
- Beijing Anzhen Hospital
Diabetes Mellitus, Kidney Transplant; Complications
Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus
This EmLina Renal trial is an investigator initiated, single-center, prospective, open-label, randomized clinical study to examine the safety and effect of empagliflozin 25 mg once a day vs.
- Trial name
- EmLina Renal (NCT06098625)
- Testing
- Empagliflozin 25 MG, Linagliptin 5 mg Oral Tablet
- Volunteers
- 200 people
- Sponsor
- Medanta, The Medicity, India